rs112655778 - LINC01776 - SNX7-DT
Magnitude 2.2 · 1 study on file
Reported associations
-
Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1 - Unknown journal (n.d.) · Unknown authors · PubMed 28115739
ABSTRACT: Opioids are very effective analgesics, but they are also highly addictive. Methadone is used to treat opioid dependence (OD), acting as a selective agonist at the μ-opioid receptor encoded by the gene OPRM1. Determining the optimal methadone maintenance dose is time-consuming; currently, no biomarkers are available to guide treatment. In methadone-treated OD subjects drawn from a case and control sample, we conducted a genome-wide association study (GWAS) of usual daily methadone dose. In African-American (AA) OD subjects (n = 383), we identified a genome-wide significant association between therapeutic methadone dose (mean = 68.0 mg, standard deviation (SD) = 30.1 mg) and rs73568641 (P = 2.8 × 10−8), the nearest gene (306 kilobases) being OPRM1. Each minor (C) allele corresp
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
methadone dosing with addiction provider Moderate
The A allele is associated with higher methadone maintenance doses required for opioid dependence treatment.
Share genetic test results with addiction medicine specialist if you have opioid use disorder.